ProductsBack/Immunoglobulin G Fc Fragment

Immunoglobulin G Fc Fragment

Name: Immunoglobulin G Fc Fragment
SKU: 16-16-090707-FC_A95
Availability: BackOrder

16-16-090707-FC

Product group Proteins / Signaling Molecules

Overview

Supplier
Athens Research
Product Name
Immunoglobulin G Fc Fragment
Delivery Days Customer
9
Applications Supplier
Flow Cytometry, ELISA, Antisera Production, In Vitro Diagnostics, Proteomics
Certification
Research Use Only
Estimated Purity
≥95% by SDS-PAGE., No reaction by IEP to antisera to human IgG-fab.
Scientific Description
The Fc (fragment crystallizable) region of immunoglobulin G, while not binding antigen, contains crucial biological activities and antigenic determinants. This homodimeric glycoprotein comprises CH2 and CH3 domains and mediates immune effector functions through interactions with Fc receptors, C1q, and FcRn. Fc fragments orchestrate antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and phagocytosis while controlling IgG's serum half-life via pH-dependent FcRn binding. The conserved N-linked glycosylation at Asn-297 is essential for structural stability and receptor interactions. Altered Fc glycosylation patterns correlate with autoimmune conditions including rheumatoid arthritis, where reduced galactosylation and sialylation indicate inflammatory disease states. Fc receptor polymorphisms are also associated with autoimmune disease development.
Shelf life instruction
more then 1 year
Source
Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
Storage Instruction
≤ -80° C
UNSPSC
41116100

Zeng, J., et al., (2019), 'Rare missense variants in the human cytosolic antibody receptor preserve antiviral function', eLife, 8: pp. e48339.
Read this paper
Zhang, P., et al., (2020), 'Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies', Cancers, 12: pp. 284
Read this paper
Wang, X., et al., (2022), 'CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder', Cell Metabolism, 34: pp. 1088–1103
Read this paper
Liu M., et al., (2023), Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4– and PD-1–targeted immunotherapy', Sci. Transl. Med., 15 (685), eabm5663
Read this paper
Li, Y., et al., (2024), 'CD177 is a novel IgG Fc receptor and CD177 genetic variants affect IgG-mediated function', Front. Immunol. 15:1418539.
Read this paper